Cancer: Thyroid | eHealth News | Page 7

The kinase inhibitor Lenvima (lenvatinib) has been approved by the U.S. Food and Drug Administration to treat differentiated thyroid cancer that has progressed despite radioactive iodine therapy

FDA Approves Lenvima for Type of Thyroid Cancer

HealthDay.com - Feb 13, 2015

To treat differentiated thyroid cancer that has progressed despite radioactive iodine therapy

Oral lenvatinib delayed progression of advanced thyroid cancer by 18 months

Lenvatinib Delays Progression in Advanced Thyroid Cancer

HealthDay.com - Feb 12, 2015

Leads to improvement in progression-free survival for radioiodine-refractory thyroid cancer

1...5 67Page 7 of 7

Archives